Biomarker ID | 24 |
PMID | 10999725 |
Year | 2000 |
Biomarker | Caveolin-1 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in African American Men (AA: 39% vs WA: 17%) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Endothelial NOS activation,VEGFR1 pathway,Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis,Nitric oxide metabolism,ALK1 pathway |
Experiment | African Americans vs White American men with Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | 71 White American and 71 African American men with Prostate Cancer were compared |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0048 |
Method Used | Quantitative Immunostaining |
Clinical | No |
Remarks | caveolin-1, bcl-2, p53, and c-myc were used as biomarkers to test whether they were differentially expressed in African American vs White men. Only caveolin-1 was found to be Differentially expressed |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on external patient cohort |
Technical Name | CAV1 |